<HashMap><database>biostudies-literature</database><scores/><additional><submitter>van der Kaaij A</submitter><funding>The International Coordination of Research on Infectious Animal Diseases</funding><funding>Eurostars</funding><funding>Netherlands Organisation for Scientific Research, Veni grant</funding><funding>Dutch Research Council (NWO)</funding><funding>The center for unusual collaboration (CUCo)</funding><pagination>224-238</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12854890</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(1)</volume><pubmed_abstract>Glycosylation is an important aspect for many biopharmaceuticals, including vaccines against parasitic helminths. Plants, especially Nicotiana benthamiana, have proven to be excellent production hosts for biopharmaceuticals with tailor-made glycosylation. If desired, galactosylation can be introduced on biopharmaceuticals through co-expression of the appropriate glycosyltransferase. However, achieving homogenous glycoforms with terminal galactose residues remains difficult as native N. benthamiana β-galactosidases (NbBGALs) truncate these glycans. Recently, the first NbBGAL has been identified, but a knockout line was insufficient to achieve near complete galactosylation, suggesting that other enzymes could have similar activity. In this study, we selected 10 NbBGALs for further investigat</pubmed_abstract><journal>Plant biotechnology journal</journal><pubmed_title>Identification of β-galactosidases along the secretory pathway of Nicotiana benthamiana that collectively hamper engineering of galactose-extended glycans on recombinant glycoproteins.</pubmed_title><pmcid>PMC12854890</pmcid><funding_grant_id>16740</funding_grant_id><funding_grant_id>E! 115017</funding_grant_id><pubmed_authors>Bunte MJM</pubmed_authors><pubmed_authors>Mokhtari S</pubmed_authors><pubmed_authors>Schots A</pubmed_authors><pubmed_authors>Wilbers RHP</pubmed_authors><pubmed_authors>Nijhof L</pubmed_authors><pubmed_authors>Nibbering P</pubmed_authors><pubmed_authors>van der Kaaij A</pubmed_authors><pubmed_authors>Overmars H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Identification of β-galactosidases along the secretory pathway of Nicotiana benthamiana that collectively hamper engineering of galactose-extended glycans on recombinant glycoproteins.</name><description>Glycosylation is an important aspect for many biopharmaceuticals, including vaccines against parasitic helminths. Plants, especially Nicotiana benthamiana, have proven to be excellent production hosts for biopharmaceuticals with tailor-made glycosylation. If desired, galactosylation can be introduced on biopharmaceuticals through co-expression of the appropriate glycosyltransferase. However, achieving homogenous glycoforms with terminal galactose residues remains difficult as native N. benthamiana β-galactosidases (NbBGALs) truncate these glycans. Recently, the first NbBGAL has been identified, but a knockout line was insufficient to achieve near complete galactosylation, suggesting that other enzymes could have similar activity. In this study, we selected 10 NbBGALs for further investigat</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-06-09T06:47:30.796Z</modification><creation>2026-06-09T03:11:52.113Z</creation></dates><accession>S-EPMC12854890</accession><cross_references><pubmed>40333706</pubmed><doi>10.1111/pbi.70126</doi></cross_references></HashMap>